Similar articles for PMID: 16636341

Year	Number of Results
1982	1
1987	1
1991	1
1993	1
1994	1
2000	1
2001	1
2002	1
2003	3
2004	1
2005	7
2006	17
2007	25
2008	18
2009	31
2010	45
2011	38
2012	30
2013	5
2014	5
2015	5
2016	1
2017	1
2018	6
2019	2
2020	4
2021	3
2022	2
2024	0

1

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.

Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ. Ratain MJ, et al. J Clin Oncol. 2006 Jun 1;24(16):2505-12. doi: 10.1200/JCO.2005.03.6723. Epub 2006 Apr 24. J Clin Oncol. 2006. PMID: 16636341 Clinical Trial.

2

Sorafenib for the treatment of advanced renal cell carcinoma.

Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R, Pazdur R. Kane RC, et al. Clin Cancer Res. 2006 Dec 15;12(24):7271-8. doi: 10.1158/1078-0432.CCR-06-1249. Clin Cancer Res. 2006. PMID: 17189398 Review.

3

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM. Escudier B, et al. J Clin Oncol. 2009 Jul 10;27(20):3312-8. doi: 10.1200/JCO.2008.19.5511. Epub 2009 May 18. J Clin Oncol. 2009. PMID: 19451442 Clinical Trial.

4

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.

Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM; ARCCS Study Investigators. Stadler WM, et al. Cancer. 2010 Mar 1;116(5):1272-80. doi: 10.1002/cncr.24864. Cancer. 2010. PMID: 20082451 Free article.

5

Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.

Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S. Akaza H, et al. Jpn J Clin Oncol. 2007 Oct;37(10):755-62. doi: 10.1093/jjco/hym095. Epub 2007 Oct 19. Jpn J Clin Oncol. 2007. PMID: 17951335 Clinical Trial.

6

Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.

Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Autier J, et al. Arch Dermatol. 2008 Jul;144(7):886-92. doi: 10.1001/archderm.144.7.886. Arch Dermatol. 2008. PMID: 18645140 Clinical Trial.

7

Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.

Mancuso A, Di Paola ED, Leone A, Catalano A, Calabrò F, Cerbone L, Zivi A, Messina C, Alonso S, Vigna L, Caristo R, Sternberg CN. Mancuso A, et al. BJU Int. 2012 Jan;109(2):200-6. doi: 10.1111/j.1464-410X.2011.10421.x. BJU Int. 2012. PMID: 22212284 Clinical Trial.

8

Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.

Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Antoun S, et al. J Clin Oncol. 2010 Feb 20;28(6):1054-60. doi: 10.1200/JCO.2009.24.9730. Epub 2010 Jan 19. J Clin Oncol. 2010. PMID: 20085939 Clinical Trial.

9

Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.

Blumenschein GR Jr, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M. Blumenschein GR Jr, et al. J Clin Oncol. 2009 Sep 10;27(26):4274-80. doi: 10.1200/JCO.2009.22.0541. Epub 2009 Aug 3. J Clin Oncol. 2009. PMID: 19652055 Clinical Trial.

10

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP. Rini BI, et al. J Clin Oncol. 2009 Sep 20;27(27):4462-8. doi: 10.1200/JCO.2008.21.7034. Epub 2009 Aug 3. J Clin Oncol. 2009. PMID: 19652060 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

231 results

Results by year